Full Length Research Paper
References
|
Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD (1998). Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670-1677. Crossref |
||||
|
Chen HC, Chou CK, Sun CM, Yeh SF (1997). Suppressive effects of destruxin B on hepatitis B virus surface antigen gene expression in human hepatoma cells. Antiviral Res. 34:137-144. Crossref |
||||
|
Cooke GS, Main J, Thursz MR (2010). Treatment for hepatitis B. BMJ 340:b5429. Crossref |
||||
|
Czaja AJ (1979). Serologic markers of hepatitis A and B in acute and chronic liver disease. Mayo Clin Proc 54: 721-732. |
||||
|
Hoofnagle JH (2009). Reactivation of hepatitis B. Hepatology 49:S156-165. Crossref |
||||
|
Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, Liao YM, Li CC, Wu HB, Tien HF, Chao TY, Liu TW, Cheng AL, Chen PJ (2008). A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 47:844-853. Crossref |
||||
|
Klaunig JE, Goldblatt PJ, Hinton DE, Lipsky MM, Chacko J, Trump BF (1981). Mouse liver cell culture. I. Hepatocyte isolation. In Vitro 17:913-925. Crossref |
||||
|
Knowles BB, Howe CC, Aden DP (1980). Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209:497-499. Crossref |
||||
|
Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N (2005). Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352:2682-2695. Crossref |
||||
|
Mosmann T (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63. Crossref |
||||
|
Ou HT, Shieh CJ, Chen JY, Chang HM (2005). The antiproliferative and differentiating effects of human leukemic U937 cells are mediated by cytokines from activated mononuclear cells by dietary mushrooms. J. Agric. Food Chem. 53:300-305. Crossref |
||||
|
Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ (2008). Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect. Dis. 8:167-178. Crossref |
||||
|
Shaw T, Bartholomeusz A, Locarnini S (2006). HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 44:593-606. Crossref |
||||
|
Twist EM, Clark HF, Aden DP, Knowles BB, Plotkin SA (1981). Integration pattern of hepatitis B virus DNA sequences in human hepatoma cell lines. J. Virol. 37:239-243. |
||||
|
Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NYW, Zee B, Johnson PJ (2000). Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J. Med. Virol. 62:299-307. Crossref |
||||
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
